MASH is a chronic and progressive liver disease characterised by fat accumulation and inflammation in the liver,
The new tests can support clinical decision making when prescribing direct oral anticoagulants for stroke prevention
These re-agent and diagnostic test kits come with 99.7% accuracy
About 75% of all primary liver cancers in adults are HCC and up to 30% of HCC patients are eligible for embolisation
This Phase III clinical trial is a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and efficacy of ASC40
Keynote -564 is the first Phase 3 trial to demonstrate superior overall survival (OS) with adjuvant therapy compared to placebo in patients with RCC
Hearing restoration was observed within 30 days of a single administration of AK-OTOF in the initial AK-OTOF-101 study participant
Denifanstat achieved statistically significant results on primary and multiple secondary endpoints in a 52-week clinical trial
The orphan drug designation by the EC is issued for drugs which are intended to treat diseases that affect fewer than five in 10,000 people in the European Union
Collaboration provides AstraZeneca with exclusive rights to Omniose’s proprietary bioconjugation platform to explore potential vaccines for a broad range of bacterial pathogens
Comprehensive clinical development programs being initiated for each investigational candidate
Base4's drug discovery platform allows its collaborators to evaluate billions of novel small molecules to identify and progress RNA-modulators for important diseases
Innovent will supply sintilimab for the collaborated clinical trial
Innovent also obtains an exclusive option to license in the future development, manufacturing and commercialization rights of SGB-3908
Leading USA based genetic testing brand officially enters the Indian market
Accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
Almost 300 million people globally have chronic hepatitis B
Phase 3 data expected in the second half of 2024
Impressive safety and efficacy for solid cancer patients followed by global clinical study plan
LG Chem is making progress in the development of the world's first oral treatment for rare forms of obesity.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)
